Pfizer Inc
NYSE:PFE
Pfizer Inc
Revenue
Pfizer Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$8.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Pfizer Inc
Revenue Breakdown
Breakdown by Geography
Pfizer Inc
Total Revenue:
58.5B
USD
|
United States:
27.1B
USD
|
Emerging Markets:
12B
USD
|
Developed Europe:
11.7B
USD
|
Developed Rest Of World:
7.8B
USD
|
Breakdown by Segments
Pfizer Inc
Total Revenue:
58.5B
USD
|
Biopharma:
57.2B
USD
|
Comirnaty Direct Sales And Alliance Revenues:
11.2B
USD
|
Eliquis Alliance Revenues And Direct Sales:
6.7B
USD
|
Prevnar Family:
6.4B
USD
|
Ibrance:
4.8B
USD
|
Vyndaqel Family:
3.3B
USD
|
All Other Specialty Care:
2.2B
USD
|
All Other Primary Care:
1.8B
USD
|
Xeljanz:
1.7B
USD
|
Business Innovation Segment:
1.3B
USD
|
Paxlovid:
1.3B
USD
|
Pfizer Centreone:
1.3B
USD
|
Xtandi Alliance Revenues:
1.2B
USD
|
All Other Anti-Infectives:
1.1B
USD
|
Inlyta:
1B
USD
|
Nurtec Odt/Vydura:
928m
USD
|
Abrysvo:
890m
USD
|
Enbrel (Outside The United States And Canada):
830m
USD
|
Sulperazon:
757m
USD
|
Bosulif:
645m
USD
|
Ig Portfolio:
584m
USD
|
Genotropin:
539m
USD
|
Lorbrena:
539m
USD
|
Zavicefta:
511m
USD
|
Inflectra:
490m
USD
|
All Other Oncology:
433m
USD
|
Benefix:
424m
USD
|
Zirabev:
424m
USD
|
Zithromax:
406m
USD
|
Premarin Family:
397m
USD
|
Ruxience:
390m
USD
|
Xalkori:
374m
USD
|
Retacrit:
340m
USD
|
Medrol:
339m
USD
|
Bmp2:
338m
USD
|
Oxbryta:
328m
USD
|
Aromasin:
301m
USD
|
Fsme-Immun/Ticovac:
268m
USD
|
Somavert:
267m
USD
|
Fragmin:
238m
USD
|
Besponsa:
236m
USD
|
Refacto Af/Xyntha:
230m
USD
|
Braftovi:
213m
USD
|
Cresemba:
195m
USD
|
Bavencio Alliance Revenues:
190m
USD
|
Vfend:
187m
USD
|
Sutent:
180m
USD
|
Nimenrix:
179m
USD
|
Mektovi:
174m
USD
|
Bicillin:
158m
USD
|
Cibinqo:
128m
USD
|
Trumenba:
126m
USD
|
Trazimera:
91m
USD
|
Padcev:
52m
USD
|
Adcetris:
46m
USD
|
Pfizer Ignite:
44m
USD
|
Tukysa:
17m
USD
|
Tivdak:
4m
USD
|
See Also
What is Pfizer Inc's Revenue?
Revenue
58.5B
USD
Based on the financial report for Dec 31, 2023, Pfizer Inc's Revenue amounts to 58.5B USD.
What is Pfizer Inc's Revenue growth rate?
Revenue CAGR 10Y
1%
Over the last year, the Revenue growth was -42%. The average annual Revenue growth rates for Pfizer Inc have been 12% over the past three years , 7% over the past five years , and 1% over the past ten years .